Objective: Parkinson's disease (PD) is characterized by degeneration in the mesolimbic and mesocortical dopamine projections, which is thought to contribute directly to the prevalence of depression in affected individuals. The present study examined the effects of different medications of depressive symptoms as measured by the Geriatric Depression Scale (GDS). Method: A derived dataset of PD cases (N = 1948) from The National Alzheimer's Coordinating Center (NACC) was used for this study. A hierarchal regression was used to test the impact of Parkinsonian drugs on depression scores via the GDS with additional tests of this model when accounting for change in scores via antidepressants and anxiolytics. Results. The model showed a significant change in scores with patients treated with Parkinsonian drugs including MAOI inhibitors, Dopamine Agonists, and Dopamine Replacement (R = 0.160, F = 12.498, p < .0001). When assessing the significant predictors in the final model, MAOI inhibitors (B =...

Article PDF first page preview

Article PDF first page preview
Article PDF first page preview
You do not currently have access to this article.